KRAS and neoplasm: The therapeutic index of pan-RAS inhibitors will depend on the effects of targeting mutant RAS (KRAS, HRAS or NRAS) oncogene addiction in tumour cells compared to the effect on normal cells when activated RAS is inhibited.